Effect of Diabetes on Long-Term Mortality Following Contemporary Percutaneous Coronary Intervention
- 1 May 2004
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (5) , 1137-1142
- https://doi.org/10.2337/diacare.27.5.1137
Abstract
OBJECTIVE—Diabetic patients are known to have reduced long-term survival following percutaneous transluminal coronary angioplasty compared with nondiabetic patients. However, it is unknown whether this survival disadvantage has persisted in the era of contemporary percutaneous coronary intervention (PCI) techniques, which include the widespread use of stents and the availability of platelet glycoprotein (GP) IIb/IIIa inhibitors. RESEARCH DESIGN AND METHODS—Three hospitals in New York City contributed prospectively defined data on 4,284 patients undergoing PCI. The primary end point was all-cause mortality following hospital discharge for PCI. RESULTS—Hypertension, renal insufficiency, and renal failure requiring dialysis were all more common in diabetic patients, whereas active smoking was less frequent. Congestive heart failure on admission was more common in diabetic than nondiabetic patients (7.7 vs. 4.0%, P < 0.001). Stents were placed in 78% of nondiabetic patients and 75% of diabetic patients (P = 0.045). Platelet GP IIb/IIIa antagonists were administered to 23% of nondiabetic and 24% of diabetic patients (P = NS). At a mean follow-up of 3 years, mortality was 8% among nondiabetic patients and 13% for diabetic patients (P < 0.001). After adjustment for differences in baseline characteristics between nondiabetic and diabetic patients, diabetes remained a significant independent hazard for late mortality (hazard ratio 1.462, 95% CI 1.169–1.828; P = 0.001). CONCLUSIONS—Following contemporary PCI, diabetic patients continue to have worse survival than nondiabetic patients.Keywords
This publication has 38 references indexed in Scilit:
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction fn1fn1The GUSTO-I study was supported by a combined grant from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genetech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.Journal of the American College of Cardiology, 1997
- Can restenosis after coronary angioplasty be predicted from clinical variables?Journal of the American College of Cardiology, 1993
- Evidence for abnormal platelet glycoprotein expression in diabetes mellitusEuropean Journal of Clinical Investigation, 1990
- Repeat coronary angioplasty for restenosis: Results and predictors of follow-up clinical eventsAmerican Heart Journal, 1989
- Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosisThe American Journal of Cardiology, 1989
- Multiple vessel coronary angioplasty: Classification, results, and patterns of restenosis in 494 consecutive patientsCatheterization and Cardiovascular Diagnosis, 1987
- Lipids, diabetes, and coronary heart disease: Insights from the Framingham StudyAmerican Heart Journal, 1985
- Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood instituteThe American Journal of Cardiology, 1984
- Diabetes and cardiovascular disease. The Framingham studyJAMA, 1979